In Vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in canadian hospitals from 2010 to 2012: Results from the CANWARD surveillance study

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5600-5611

  Karlowsky, James A ^a   Adam, Heather J ^a   Baxter, Melanie R ^a   Lagacé Wiens, Philippe R S ^a   Walkty, Andrew J ^a,b   Hoban, Daryl J ^a   Zhanel, George G ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AVIBACTAM; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAROLINE; CEFTAROLINE PLUS AVIBACTAM; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; CANADA; CITROBACTER FREUNDII; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CANADA; CEPHALOSPORINS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PUBLIC HEALTH SURVEILLANCE; RETROSPECTIVE STUDIES;

EID: 84885930750     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01485-13     Document Type: Article

References (34)

1. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2012. Summary of ceftaroline activity against pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob. Agents Chemother. 56: 2933-2940.
2. Karlowsky JA, Adam HJ, DeCorby MR, Lagacé-Wiens PRS, Hoban DJ, Zhanel GG. 2011. In vitro activity of ceftaroline against Grampositive and Gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob. Agents Chemother. 55:2837-2846.
3. Patel SN, Pillai MD, Pong-Porter S, McGeer A, Green K, Low DE. 2009. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J. Antimicrob. Chemother. 64:659-660.
4. Sader HS, Flamm RK, Jones RN. 2013. Antimicrobial activity of ceftaroline-Avibactam tested against clinical isolates collected from U.S. medical centers in 2010-2011. Antimicrob. Agents Chemother. 57:1982-1988.
5. Saravolatz L, Pawlak J, Johnson L. 2010. In vitro activity of ceftaroline against community-Associated methicillin-resistant, vancomycinintermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:3027-3030.
6. Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Legacé-Wiens PRS, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. 2009. Ceftaroline: A novel broad-spectrum cephalosporin with activity against meticillinresistant Staphylococcus aureus. Drugs 69:809-831.
7. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJC. 2010. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob. Agents Chemother. 54:1627-1632.
8. Goldstein EJC, Citron DM, Merriam CV, Tyrrell KL. 24 April 2013. Comparative in vitro activity of ceftaroline, ceftaroline-Avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. Diagn. Microbiol. Infect. Dis. http://dx.doi.org/10.1016/j.diagmicrobio.2013.03.019.
9. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. 2007. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60: 300-311.
10. Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN. 2012. Activity of ceftaroline-Avibactam tested against Gram-negative organism populations, including strains expressing one or more -lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob. Agents Chemother. 56: 4779-4785.
11. Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N. 2012. Characterization of -lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline avibactam (NXL104). J. Antimicrob. Chemother. 67:1354-1358.
12. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. 2010. Activity of chequerboard combinations of ceftaroline and NXL104 versus -lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65:1428-1432.
13. Sader HS, Castanheira M, Flamm RK, Jones RN. 2012. Antimicrobial activity of ceftaroline-Avibactam tested against clinical Enterobacteriaceae isolates carrying multiple -lactamases from USA medical centers, abstr A660. Abstr. 112th Gen. Meet. Am. Soc. Microbiol., San Francisco, CA, 16 to 19 June 2012.
14. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2013. Ceftazidime-Avibactam: A novel cephalosporin/-lactamase inhibitor combination. Drugs 73:159-177.
15. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-lactam -lactamase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 109:11663-11668.
16. Lahiri SD, Mangani S, Durand-Reville T, Benvenuti M, De Luca F, Sanyal G, Docquier J-D. 2013. Structural insight into potent broadspectrum inhibition with reversible recyclization mechanism: Avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC -lactamases. Antimicrob. Agents Chemother. 57:2496-2505.
17. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Mulvey MR, Bryce E, Boyd D, Ofner-Agostini M, Christianson S, Simor AE, Paton S, Canadian Hospital Epidemiology Committee, Canadian Nosocomial Infection Surveillance Program, Health Canada. 2004. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob. Agents Chemother. 48:1204-1214.
20. Nuesch-Inderbinen MT, Hachler H, Kayser FH. 1996. Detection of genes coding for extended-spectrum SHV beta-lactamases in clinical isolates by a molecular genetic method, and comparison with the Etest. Eur. J. Clin. Microbiol. Infect. Dis. 15:398-402.
21. Speldooren V, Heym B, Labia R, Nicolas-Chanoine M-H. 1998. Discriminatory detection of inhibitor-resistant -lactamases in Escherichia coli by single-strand conformation polymorphism-PCR. Antimicrob. Agents Chemother. 42:879-884.
22. Baudry PJ, DeCorby M, Mataseje L, Mulvey MR, Hoban DJ, Zhanel GG. 2008. Comparison of antimicrobial resistance profiles among extended-spectrum-beta- lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units. Antimicrob. Agents Chemother. 52:1846-1849.
23. Caroff N, Espaze E, Berard I, Richet H, Reynaud A. 1999. Mutations in theampCpromoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum beta-lactamase production. FEMS Microbiol. Lett. 173:459-465.
24. McDonald RR, Antonishyn NA, Hansen T, Snook LA, Nagle E, Mulvey MR, Levett PN, Horsman GB. 2005. Development of a triplex real-Time PCR assay for detection of Panton-Valentine leukocidin toxin genes in clinical isolates of methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:6147-6149.
25. Golding GR, Campbell JL, Spreitzer DJ, Veyhl J, Surynicz K, Simor A, Mulvey MR, Canadian Nosocomial Infection Surveillance Program. 2008. A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field gel electrophoresis epidemic type using spa typing. Can. J. Infect. Dis. Med. Microbiol. 19:273-281.
26. Bebrone C, Lassaux P, Vercheval L, Sohier J, Jehaes A, Sauvage E, Galleni M. 2010. Current challenges in antimicrobial chemotherapy: Focus on beta-lactamase inhibition. Drugs 70:651-679.
27. Brown SD, Traczewski MM. 2009. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob. Agents Chemother. 53:1271-1274.
28. Ge Y, Biek D, Talbot GH, Sahm DF. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398-3407.
29. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. 2005. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49:3501-3512.
30. Mushtaq S, Livermore DM. 2010. AmpC induction by ceftaroline. J. Antimicrob. Chemother. 65:586-588.
31. Kosowska-Shick K, McGhee PL, Appelbaum PC. 2010. Affinity of ceftaroline and other -lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 54:1670-1677.
32. Sader HS, Flamm RK, Jones RN. 2013. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob. Agents Chemother. 57:3178-3181.
33. Wiskirchen D, Crandon JL, Furtado GH, Williams G, Nicolau DP. 2011. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:3220-3225.
34. Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, VanScoy B, Kulawy R, Drusano GL. 2012. Pharmacodynamics of -lactamase inhibition by NXL104 in combination with ceftaroline: Examining organisms with multiple types of -lactamases. Antimicrob. Agents Chemother. 56:258-270.